Ress Life Investments A/S
6.1.2021 13:12:11 CET | Globenewswire | Press release
Ress Life Investments A/S
Holbergsgade 14, 2 tv
DK-1057 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 6 January 2021
Corporate Announcement 01/2021
Ress Life Investments A/S announces the events of the annual general meeting
held on 6 January 2021.
At the annual general meeting of Ress Life Investments A/S held on Wednesday 6 January 2021, the following decisions were taken:
• The 2019/2020 Annual Report was approved – cf item 1 of the agenda.
• Appropriation of the year's result was approved - cf item 2 of the agenda.
• Søren Andersen, Jeppe Buskov, Ketil Petersen and Anne Buchardt were re-elected to the Board of Directors - cf item 3 of the agenda.
• The Remuneration Policy and the Remuneration Report was approved - cf item 4 of the agenda.
• The remuneration of the Board of Directors for the financial year 2020/2021 was
approved – cf item 5 of the agenda.
• Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as auditor – cf
item 6 of the agenda.
Questions related to this announcement can be made to the company’s AIF-manager, Resscapital AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@resscapital.com
Tel +46 7 366 072 42
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
